Press Center

We invite you to a webinar on antitrust risks for pharmaceutical companies when setting prices for medicinal products.

As part of the implementation of the Strategy for the Development of the Pharmaceutical Industry through 2030, approved by Decree of the Government of the Russian Federation No. 1495-r of 7 June 2023 (“Pharma Strategy 2030”), and discussions at the “Healthy Society” forum organized by the Roscongress Foundation with the support of the Ministry of Health (16–17 March 2026, Moscow) (“Forum”), key areas of state support for domestic drug developers and manufacturers were identified, including subsidies for clinical trials .

In addition to existing support programs, subsidies for clinical trials at all stages will help overcome the financing barrier for high-risk phases of medicines clinical trials and accelerate the market launch of medicines. The combination of current and planned measures will create the legal and economic foundation for strengthening the production and technological capacity of the domestic pharmaceutical industry and increasing its presence in international markets.

Below, we will examine planned initiatives and support measures for pharmaceutical manufacturers that have already been implemented.

On May 26, Moscow will host the XVII Antitrust Forum — the flagship event in Russian competition law. The forum is traditionally held with the support of the Federal Antimonopoly Service of Russia (FAS Russia) and the Association of Antimonopoly Experts (AAE). This year’s main theme is competition in the digital economy.

Lidings is an official partner of the forum and is organising a special session: “Pharmaceuticals & Antitrust: The Fight for Fair Competition Amid Economic Challenges.”

The Lidings team, led by Managing Partner Boris Malakhov and including Senior Associate Vladislav Ryabov, Associate Ivan Vasiliev, and Junior Associate Alena Troitskaya, advised the client in the dispute concerning intellectual property and brand protection in the Russian Federation.

Join us and fellow experts to explore how the 2026 amendments to corporate law simplify M&A transactions, eliminate the pre-emptive right to purchase shares, and allow the structuring of holding companies without unnecessary restrictions.

The article provides an algorithm for recovering the full value of assets instead of the price difference when a transaction is challenged due to inadequate consideration.

On April 24, 2026, the First All-Russian Conference of Young Specialists "LAW_EXPO" was held at St. Petersburg State University. The event brought together scholars, leading expert practitioners, and early-career researchers for a comprehensive analysis of key issues in information law.

Alina Smakova, an associate in the Data Protection & Technology practice at Lidings, took part in the conference.

On 29 April 2026, the Constitutional Court of the Russian Federation (the “CCRF”) has published its case law review for the first quarter of 2026, comprising 19 judgments and 6 rulings. The document systematizes decisions across administrative, labor, private and criminal law, establishing new standards for the protection of individuals and businesses.

On March 30, 2026, the State Duma received bill №. 1191453-8 (hereinafter "bill"), which is planned to amend the CPC norm on alternative jurisdiction. The subject of the legislative initiative was the Government of the Russian Federation.

On April 21, 2026, the State Duma adopted Bill No. 1077246-8 in its third reading, introducing amendments to the Code of Administrative Offenses of the Russian Federation (CAO RF). These innovations are aimed at expanding the rights of participants in administrative offense proceedings and unifying procedural legislation.